Turenne backs ABL Lyon

The management team, led by CEO Marc Essodaigui, reinvested in the company and retained a minority stake.

Following the deal, ABL Lyon will be renamed to Active Biomarkers.

The GP invested in the company via Turenne Capital Santé 2, which targets profitable French SMEs operating across the healthcare sector. The fund was originally launched with a €150m target and held a first closing on €100m in March 2019. 

The vehicle has raised more than €145m so far and increased its hard-cap to €165m. It expects to hold a final close by the end of the year.

Turenne intends to support ABL in consolidating its market position and strengthening its existing commercial partnerships, while boosting its expansion and gaining new customers. ABL also plans to bolster the development of its production and R&D capacity, enlarge its portfolio of proprietary assets and evaluate external growth opportunities.

Company
Founded in 2011, ABL Lyon specialises in immunobiology, offering biomarker testing and analysis to biopharmaceutical companies during all the phases of their clinical research programmes, from discovery to clinical stages.

The business specialises in various therapeutic fields, including oncology, infectious diseases, inflammatory pathologies and neurodegenerative diseases.

People
Turenne Santé – Mounia Chaoui, Paul Chamoulaud (partners).
ABL Lyon – Marc Essodaigui (CEO).

Advisers
Equity – Jeantet (legal); Aequifi (corporate finance).
Company – CFI Group (corporate finance); Viajuris (legal).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• France
• Healthcare
• Turenne Capital Partenaires
• France